
VYVGART & VYVGART Hytrulo
VYVGART (efgartigimod alfa-fcab) is a treatment that uses a fragment of an IgG antibody to treat adults with anti-AChR antibody positive generalized myasthenia gravis (gMG).
VYVGART Hytrulo is a combination of efgartigimod alfa, a neonatal Fc receptor blocker, and hyaluronidase, an endoglycosidase, indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.
For more information, visit the patient website for this drug. Speak with your healthcare provider to learn if this drug is right for you.
What it treats
Myasthenia Gravis
Prescribed by
Neurologists
How it’s administered
Intravenous (IV) infusion
Frequency
Once a week for four weeks
Length of treatment
60 minutes